Coverage
Filings
| Filing | Date |
|---|---|
| Statement: Zantac (ranitidine) litigation | 29 Jul 2024 |
| Blenrep EMA Filing Acceptance | 19 Jul 2024 |
| Director/PDMR Shareholding | 18 Jul 2024 |
| Director/PDMR Shareholding | 16 Jul 2024 |
| Director/PDMR Shareholding | 15 Jul 2024 |
| Director/PDMR Shareholding | 12 Jul 2024 |
| GSK and CureVac collaboration restructured | 3 Jul 2024 |
| Total Voting Rights | 1 Jul 2024 |
| Statement: Zantac (ranitidine) litigation |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 28 Jun 2024 |
| EMA validates Jemperli marketing authorisation | 24 Jun 2024 |
| Omjjara approved in Japan for myelofibrosis | 24 Jun 2024 |
| Director/PDMR Shareholding | 21 Jun 2024 |